Importantly, the observed delays in tumor growth in resected animals treated with anti-CD47 mAb treatment were associated with a significantly improved outcome compared to resected animals treated with IgG control antibody (81.5 days vs 69.0 days, anti-CD47 vs IgG control; P = 0.0007). The gene discussed is CD47; the disease is neoplasm.